Citations

Clear

511 citation(s) found for "Seth, N".

Let it glow: Intraoperative visualization of pulmonary metastases using pafolacianine, a next‐generation fluorescent agent, for young adults undergoing pulmonary metastasectomy
Lehane, Alison , Polites, Stephanie F. , Dodd, Ashley , Lautz, Timothy B. , Lautz, Timothy , Goldstein, Seth D.

Mayo Clinic

Pediatric Blood & Cancer | August 28, 2024 | Volume: 71 | Issue: 11 | Pages: No page available

10.1002/pbc.31293 | PMID 39192706 Get It

AbstractA new generation of disease‐specific molecular imaging agents is poised to revolutionize fluorescence‐guided surgery. Pafolacianine has been approved for adult lung and ovarian cancers. We demonstrate a proof of concept for pediatric surgeons treating young adults with pulmonary metastatic sarcomas. Five successful fluorescence‐guided pulmonary metastasectomy operations were performed in young adult patients with metastatic osteosarcoma or Ewing sarcoma following administration of pafolacianine. All osteosarcoma lesions identified using standard techniques were also markedly fluorescent in patients. Novel fluorescent molecular agents targeted to tumor‐specific receptors have promise of increased sensitivity and specificity for detecting metastatic nodules and enhancing surgical clearance of disease.
Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling
Pant, Kishor , Richard, Seth , Baral, Subheksha, Yang, Rendong , Ren, Yanan , Gradilone, Sergio A. , Masyuk, Tatyana V. , Gradilone, Sergio A , Peixoto, Estanislao , LaRusso, Nicholas F.

Mayo Clinic

Hepatology | August 26, 2024 | Volume: 81 | Issue: 4 | Pages: 1132-1145

10.1097/hep.0000000000001055 | PMID 39186465 Get It

Background and Aims: The primary cilium, an organelle that protrudes from cell surfaces, is essential for sensing extracellular signals. With disturbed cellular communication and chronic liver pathologies, this organelle’s dysfunctions have been linked to disorders, including polycystic liver disease and cholangiocarcinoma. The goal of this study was to elucidate the relationship between primary cilia and the crucial regulator of cellular proliferation, the epidermal growth factor receptor (EGFR) signaling pathway, which has been associated with various clinical conditions. Approach and Results: The study identified aberrant EGFR signaling pathways in cholangiocytes lacking functional primary cilia using liver-specific intraflagellar transport 88 knockout mice, a Pkhd1 mutant rat model, and human cell lines that did not have functional cilia. Cilia-deficient cholangiocytes showed persistent EGFR activation because of impaired receptor degradation, in contrast to their normal counterparts, where EGFR localization to the cilia promotes appropriate signaling. Using histone deacetylase 6 inhibitors to restore primary cilia accelerates EGFR degradation, thereby reducing maladaptive signaling. Importantly, experimental intervention with the histone deacetylase 6 inhibitor tubastatin A in an orthotopic rat model moved EGFR to cilia and reduced ERK phosphorylation. Concurrent administration of EGFR and histone deacetylase 6 inhibitors in cholangiocarcinoma and polycystic liver disease cells demonstrated synergistic antiproliferative effects, which were associated with the restoration of functioning primary cilia. Conclusions: This study’s findings shed light on ciliary function and robust EGFR signaling with slower receptor turnover. We could use therapies that restore the function of primary cilia to treat EGFR-driven diseases in polycystic liver disease and cholangiocarcinoma.
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia
Li, Zhenhua , Gocho, Yoshihiro , Yang, Wenjian , Crews, Kristine R. , Lee, Shawn H.R. , Roberts, Kathryn G. , Mullighan, Charles G. , Relling, Mary V. , Yu, Jiyang , Loh, Mignon L. , Saygin, Caner , Litzow, Mark R. , Karol, Seth E. , Inaba, Hiroto , Konopleva, Marina , Paietta, Elisabeth, Evans, William E. , Yang, Wenjian , Crews, Kristine R , Roberts, Kathryn G , Mullighan, Charles G , Relling, Mary V , Yu, Jiyang , Yeoh, Allen E J , Loh, Mignon L , Litzow, Mark R. , Jeha, Sima , Karol, Seth E , Inaba, Hiroto , Pui, Ching-Hon , Konopleva, Marina , Jain, Nitin , Stock, Wendy , Jabbour, Elias , Kornblau, Steven M , Yang, Jun J.J. , Yoshimura, Satoshi , Yeoh, Allen Eng Juh , Stock, Wendy , Jabbour, Elias , Kornblau, Steven M.

Mayo Clinic

Journal of Clinical Oncology | August 5, 2024 | Volume: 42 | Issue: 29 | Pages: 3478-3490

10.1200/jco.24.00500 | PMID 39102629 Get It

PURPOSE Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a strikingly higher cure rate in children compared with adults. However, the pharmacological basis of age-related differences in ALL treatment response remains unclear. METHODS Studying 767 children and 309 adults with newly diagnosed B-cell ALL enrolled on frontline trials at St Jude Children's Research Hospital, MD Anderson Cancer Center, the Alliance for Clinical Trials in Oncology, and the ECOG-ACRIN Cancer Research Group, we determined the ex vivo sensitivity of leukemia cells to 21 drugs. Twenty-three ALL molecular subtypes were identified using RNA sequencing. We systematically characterized the associations between drug response and ALL genomics in children, adolescents and young adults, and elderly adults. We evaluated the effect of age-related gene expression signature on ALL treatment outcomes. RESULTS Seven ALL drugs (asparaginase, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and inotuzumab ozogamicin) showed differential activity between children and adults, of which six were explained by age-related differences in leukemia molecular subtypes. Adolescents and young adults showed similar patterns of drug resistance as older adults, relative to young children. Mercaptopurine exhibited subtype-independent greater sensitivity in children. Transcriptomic profiling uncovered subclusters within CRLF2 -, DUX4 -, and KMT2A -rearranged ALL that were linked to age and cytotoxic drug resistance. In particular, a subset of children had adult-like ALL on the basis of leukemia gene expression patterns across subtypes, despite their chronological age. Resistant to cytotoxic drugs, children with adult-like ALL exhibited poor prognosis in pediatric ALL trials, even after adjusting for age and minimal residual diseases. CONCLUSION Our results provide pharmacogenomic insights into age-related disparities in ALL cure rates and identify leukemia prognostic features for treatment individualization across age groups.
Sex differences in altmetric attention scores and traditional impact metrics of top‐cited general surgery literature: Cracks in the ceiling?
Waqar, Usama , Siddiqui, Ayra , Waheed, Ayesha Akbar , Ahmed, Abdullah , Widad, Zara, Maqbool, Baila , Wasif, Nabil , Martins, Russell Seth , Maqbool, Baila

Mayo Clinic

World Journal of Surgery | June 19, 2024 | Volume: 48 | Issue: 9 | Pages: 2142-2149

10.1002/wjs.12253 | PMID 38890770 Get It

AbstractBackgroundSex disparities have previously been identified in surgical academia. This study examines sex differences in the top‐cited contemporary general surgery articles and compares Altimetric Attention Score (AAS) and other impact metrics between male and female corresponding authors (CAs).MethodsWe conducted a bibliometric analysis of the 100 most cited articles published between 2019 and 2021 in each of the top 10 general surgery journals based on the 2021 Journal Impact Factor. Impact metrics included AAS, citation count, and H‐index of the CA. We used multivariable regression analyses to investigate whether the sex of the CA or first author (FA) was independently associated with AAS and citation count.ResultsAmong 1000 articles, 23.1% had female CAs and 27.4% female FAs. Female CA articles had higher AAS (13.0 [2.0–63.0] vs. 8.0 [1.0–28.5]; p < 0.001) and lower H‐indices (24.0 [11.0–45.0] vs. 31.0 [17.0–50.0]; p = 0.015). Although median citation count did not differ by CA sex, articles with Level 1 evidence and a female CA were cited more often (35.5 [24.0–85.0] vs. 25.0 [16.0 vs. 46.0]; p < 0.05). In multivariable regression, female CA articles had higher AAS (OR: 1.002 [95% CI: 1.001–1.004]) and lower H‐index (OR: 0.987 [95% CI: 0.977–0.997]).ConclusionDespite having similar citation counts, articles authored by female CAs exhibit higher AAS scores compared to those authored by their male counterparts. While it is heartening that research authored by female surgeons achieves significant visibility, it remains to be understood how this translates into academic impact and scholarly recognition.
3D‐Printed Hollow Microneedles Array with Luer Lock Connection for Facile and Painless Intradermal Injection: A Proof of Concept
Ghaznavi, Amirreza , Xu, Jie , Lee, Christine U. , Hara, Seth A. , Xu, Jie

Mayo Clinic

Advanced Materials Technologies | June 15, 2024 | Volume: 9 | Issue: 18 | Pages: No page available

10.1002/admt.202400286 Get It

AbstractA 3D‐printed array of hollow microneedles (HMNs) is designed and fabricated using a high‐resolution stereolithography 3D printer and assembled with a 3D‐printed reservoir that incorporates a Luer lock mechanism, ensuring standard and secure connection to syringes. The proof‐of‐concept needle designs consist of half‐eccentric and concentric conical tip shapes, each arrayed with two different interspacing values. After the geometrical features of the devices are characterized, the devices are tested ex vivo in porcine skin to evaluate the impact of tip shape and interspacing on the depth of penetration and the efficacy of the devices in delivering fluids (such as tattoo ink) into the dermis. Overall, the 3D‐printed HMNs can deliver fluids into the target layer of skin. Refinement of the design is ongoing with the ultimate aim to provide alternatives for intradermal drug delivery and diagnostic imaging, such as superficial lymphography.
First relapse in patients with multiple myeloma: Outcomes and predictors.
Seth, S D , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hwa, Yi L. , Hobbs, Miriam, Kourelis, Taxiarchis , Warsame, Rahma , Kumar, Shaji , Seth, Sukriti, Buadi, Francis K. , Binder, Moritz , Cook, Joselle , Dispenzieri, Angela , Dingli, David , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Lin, Yi , Muchtar, Eli , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7558-7558

10.1200/jco.2024.42.16_suppl.7558 Get It

7558 Background: Survival in patients with multiple myeloma (MM) continues to improve with the newer therapies, but there is no clear evidence of a cure and patients continue to relapse. However, most patients have the most extended period without progression with their first-line therapy, and subsequent therapies often provide a shorter duration of response due to the use of drugs with overlapping mechanisms of action and, more importantly, a shorter first remission, pointing toward more aggressive disease biology. With newer immunotherapies being used at 1st relapse, this may change. We designed this study to explore the natural history of MM after the 1st relapse and define the predictors of outcome after the initial relapse. Methods: We identified all patients in the Mayo Clinic database diagnosed between Jan 2004-June 2019 who had had initial disease progression. The study cohort included 2005 patients. We explored the overall survival (OS) from the time of documented disease progression or the start of second-line treatment in patients who had not met IMWG criteria before second-line therapy. Front-line therapy was grouped into those with either an IMiD or PI, both IMiD and PI, daratumumab with IMiD and PI, and none of these agents. The IMiD and PI were always used with dexamethasone with or without an alkylator. Results: The median age was 63 (range 24-95) years and 60% were male. The median estimated follow-up from diagnosis for all patients was 86 mos. (95% CI; 82, 88) and the median time to progression from the start of therapy was 25 mos. (95% CI; 24, 26). The median OS from the first progression was 45 mos. (95% CI; 42, 50), 36 mos. for those diagnosed before 2009, and 52-53 mos. for those diagnosed later. On univariate analysis, age <70 at 1st relapse, RISS I, novel agents in initial therapy, CR in the first line, diagnosis after 2009, initial remission >18 mos, and initiation of therapy before IMWG progression were all associated with improved OS after 1st relapse (Table). On multivariate analysis, age <70, RISS I, initial remission >18 mos, and initiation of therapy before IMWG progression were all associated with improved OS after 1st relapse. Conclusions: The study provides an estimate of the outcomes and significant predictors of outcomes after 1st relapse in patients with MM. These factors should be taken into consideration when designing clinical trials in this patient population. In particular, these factors identify a high-risk group of patients not always identified by baseline characteristics and should be the focus of future trials. [Table: see text]
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.
Batist, Gerald , Cynthia, X. , Parsons, Heather A. , Twelves, Chris, Bardia, Aditya , Plourde, Paul V., Portman, David, Goetz, Matthew P. , Wander, Seth Andrew , Bachelot, Thomas , Cortés, Javier , Cristofanilli, Massimo , Curigliano, Giuseppe , Nonneville, Alexandre Tassin de , Gal‐Yam, Einav Nili , Jhaveri, Komal , Rugo, Hope S. , Sammons, Sarah , Stover, Daniel G. , Damodaran, Senthil

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS1127-TPS1127

10.1200/jco.2024.42.16_suppl.tps1127 Get It

TPS1127 Background: Patients with estrogen receptor-positive (ER+) metastatic breast cancer (mBC) may develop resistance to endocrine therapy (ET), particularly following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), potentially driven by a mutation in the ERa-coding gene, ESR1. Lasofoxifene (LAS), an oral, next-generation ET and ER breast antagonist, was evaluated in two phase 2 studies of women with ER+/HER2- mBC and an ESR1 mutation who had disease progression on previous ET and CDK4/6i. The ELAINE 1 trial showed numerically greater progression-free survival (PFS, median ~6 vs 4 mos; P=0.138), objective response rate (ORR, 13% vs 3%; P=0.124), and clinical benefit rate (CBR, 37% vs 22%; P=0.117) with LAS monotherapy versus the ER degrader fulvestrant (fulv), with a favorable safety profile (1). The single-arm, ELAINE 2 trial demonstrated that LAS plus abemaciclib (Abema) was well tolerated with a median PFS of ~13 mos, ORR of 56%, and CBR of 66% (2). Based on these data, the phase 3, registrational, ELAINE 3 trial was initiated. Methods: ELAINE 3 (NCT05696626) is an open-label, phase 3, multicenter study evaluating the efficacy, safety, and tolerability of LAS plus Abema versus fulv plus Abema. Key inclusion criteria are pre- and postmenopausal women and men aged ≥18 yrs; ER+/HER2-, locally advanced and/or mBC (measurable and/or non-measurable disease); ≥1 acquired ESR1 mutation; progression on an aromatase inhibitor plus palbociclib or ribociclib as their first hormonal treatment for advanced/mBC; and ≤1 line of chemotherapy in the advanced/metastatic setting. Patients will be randomized 1:1 to receive LAS 5 mg/day plus Abema 150 mg BID, or fulv 500 mg IM on days 1, 15, and 29, then once monthly plus Abema 150 mg BID. Treatment will continue until progression, death, unacceptable toxicity, or withdrawal from the study. The primary endpoint is PFS; key secondary endpoints are ORR, overall survival, CBR, duration of response, and time to response. Time to cytotoxic chemotherapy, quality of life, and safety will also be evaluated. Blood samples for circulating tumor DNA (ctDNA) will be collected for genomic analyses at screening, at weeks 4 and 8 and every 8 weeks thereafter, and at the final visit. Outcomes with LAS/Abema and fulv/Abema will be compared using a stratified Cox proportional hazards model and stratified logrank test. Expected PFS is ≥10.3 mos for LAS/Abema and 7 mos for fulv/Abema (PFS hazard ratio of 0.68 at final analysis). The target sample size is 400, to achieve 90% power with a one-sided type I error rate of 0.025 after 285 PFS events. Full recruitment is expected to occur over 18 mos at approximately 125 global sites. 1. Goetz MP, et al. Ann Oncol. 2023;34:1141-1151. 2. Damodaran S, et al. Ann Oncol. 2023;34:1131-1140. Clinical trial information: NCT05696626 .
Global modified‐Delphi consensus on comorbidities and prognosis of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Fitzgerald, Mark , Gardella, Elena , Hammer, Michael , Hu, Chunhui , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Waldrop, Kayla, Youngquist, J. Tyler, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2308-2321

10.1111/epi.17991 | PMID 38802989 Get It

AbstractObjectivesWe aimed to develop consensus on comorbidities (frequency, severity, and prognosis) and overall outcomes in epilepsy, development, and cognition for the five phenotypes of SCN8A‐related disorders.MethodsA core panel consisting of 13 clinicians, 1 researcher, and 6 caregivers was formed and split into three workgroups. One group focused on comorbidities and prognosis. All groups performed a literature review and developed questions for use in a modified‐Delphi process. Twenty‐eight clinicians, one researcher, and 13 caregivers from 16 countries participated in three rounds of the modified‐Delphi process. Consensus was defined as follows: strong consensus ≥80% fully agree; moderate consensus ≥80% fully or partially agree, <10% disagree; and modest consensus 67%–79% fully or partially agree, <10% disagree.ResultsConsensus was reached on the presence of 14 comorbidities in patients with Severe Developmental and Epileptic Encephalopathy (Severe DEE) spanning non‐seizure neurological disorders and other organ systems; impacts were mostly severe and unlikely to improve or resolve. Across Mild/Moderate Developmental and Epileptic Encephalopathy (Mild/Moderate DEE), Neurodevelopmental Delay with Generalized Epilepsy (NDDwGE), and NDD without Epilepsy (NDDwoE) phenotypes, cognitive and sleep‐related comorbidities as well as fine and gross motor delays may be present but are less severe and more likely to improve compared to Severe DEE. There was no consensus on comorbidities in the SeL(F)IE phenotype but strong conesensus that seizures would largely resolve. Seizure freedom is rare in patients with Severe DEE but may occur in some with Mild/Moderate DEE and NDDwGE.SignificanceSignificant comorbidities are present in most phenotypes of SCN8A‐related disorders but are most severe and pervasive in the Severe DEE phenotype. We hope that this work will improve recognition, early intervention, and long‐term management for patients with these comorbidities and provide the basis for future evidence‐based studies on optimal treatments of SCN8A‐related disorders. Identifying the prognosis of patients with SCN8A‐related disorders will also improve care and quality‐of‐life for patients and their caregivers.
Global modified Delphi consensus on diagnosis, phenotypes, and treatment of SCN8A‐related epilepsy and/or neurodevelopmental disorders
Conecker, Gabrielle , Xia, Maya , Hecker, JayEtta , Achkar, Christelle Moufawad El , Cukiert, Cristine Mella , Devries, Seth , Donner, Elizabeth , Fitzgerald, Mark P. , Gardella, Elena , Hammer, Michael F. , Hegde, Anaita , Hu, Chunhui , Luo, Tian , Kooistra, T., Waldrop, Kayla, Youngquist, J. Tyler, Zhang, Dennis, Perry, Μ. Scott , Hammer, Michael , Kato, Mitsuhiro , Schreiber, John R. , Oudin, Madeleine , Wirrell, Elaine C , Perry, Michael Scott , Fitzgerald, Mark , Gardella, Elena , Wang, Yi , Kooistra, Tammy, Wirrell, Elaine

Mayo Clinic

Epilepsia | May 28, 2024 | Volume: 65 | Issue: 8 | Pages: 2322-2338

10.1111/epi.17992 | PMID 38802994 Get It

AbstractObjectiveWe aimed to develop consensus for diagnosis/management of SCN8A‐related disorders. Utilizing a modified Delphi process, a global cohort of experienced clinicians and caregivers provided input on diagnosis, phenotypes, treatment, and management of SCN8A‐related disorders.MethodsA Core Panel (13 clinicians, one researcher, six caregivers), divided into three subgroups (diagnosis/phenotypes, treatment, comorbidities/prognosis), performed a literature review and developed questions for the modified Delphi process. Twenty‐eight expert clinicians, one researcher, and 13 caregivers from 16 countries participated in the subsequent three survey rounds. We defined consensus as follows: strong consensus, ≥80% fully agree; moderate consensus, ≥80% fully/partially agree, <10% disagree; and modest consensus, 67%–79% fully/partially agree, <10% disagree.ResultsEarly diagnosis is important for long‐term clinical outcomes in SCN8A‐related disorders. There are five phenotypes: three with early seizure onset (severe developmental and epileptic encephalopathy [DEE], mild/moderate DEE, self‐limited (familial) infantile epilepsy [SeL(F)IE]) and two with later/no seizure onset (neurodevelopmental delay with generalized epilepsy [NDDwGE], NDD without epilepsy [NDDwoE]). Caregivers represented six patients with severe DEE, five mild/moderate DEE, one NDDwGE, and one NDDwoE. Phenotypes vary by age at seizures/developmental delay onset, seizure type, electroencephalographic/magnetic resonance imaging findings, and first‐line treatment. Gain of function (GOF) versus loss of function (LOF) is valuable for informing treatment. Sodium channel blockers are optimal first‐line treatment for GOF, severe DEE, mild/moderate DEE, and SeL(F)IE; levetiracetam is relatively contraindicated in GOF patients. First‐line treatment for NDDwGE is valproate, ethosuximide, or lamotrigine; sodium channel blockers are relatively contraindicated in LOF patients.SignificanceThis is the first‐ever global consensus for the diagnosis and treatment of SCN8A‐related disorders. This consensus will reduce knowledge gaps in disease recognition and inform preferred treatment across this heterogeneous disorder. Consensus of this type allows more clinicians to provide evidence‐based care and empowers SCN8A families to advocate for their children.
Validation of a Multimarker eGFR Equation in Preserved and Reduced eGFR Using the GENOA Cohort
Tio, Maria Clarissa , Zhu, Xiaoqian , Yen, Timothy E. , Hall, Michael E. , Rule, Andrew D. , Lirette, Seth T. , Obi, Yoshitsugu , Dossabhoy, Neville R. , Shafi, Tariq

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 665-666

10.1681/asn.20233411s1665c Get It